TY - JOUR
T1 - Correction to
T2 - Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention (High Blood Pressure & Cardiovascular Prevention, (2022), 29, 2, (91-102), 10.1007/s40292-021-00503-4)
AU - Members of the Board of the Italian Society of Cardiovascular Prevention
AU - Volpe, Massimo
AU - Gallo, Giovanna
AU - Modena, Maria Grazia
AU - Ferri, Claudio
AU - Desideri, Giovambattista
AU - Tocci, Giuliano
AU - Bellone, Simonetta
AU - Bertolotti, Marco
AU - Biffi, Alessandro
AU - Consoli, Agostino
AU - Corsini, Alberto
AU - Nati, Giulio
AU - Pirro, Matteo
AU - Rubattu, Speranza
AU - Trimarco, Bruno
AU - de Kreutzenberg, Saula Vigili
AU - Volpe, Roberto
N1 - Publisher Copyright:
© The Author(s) 2022.
PY - 2022/3
Y1 - 2022/3
N2 - In the online version of the article section 8 (Obesity), para 6, lines 1 to 5 which read as: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, of the GLP1-RA semaglutide 3 mg administered weekly and the combination of naltrexone and bupropione. should read: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, the GLP1-RA liraglutide 3 mg administered daily or semaglutide 2.4 mg administered weekly and the combination of naltrexone and bupropione. In online version of the article Section 8 (Obesity), table (New recommendation), third point which reads as: Medications for weight loss in obese subjects, including orlistat, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. should read: Medications for weight loss in obese subjects, including orlistat, liraglutide, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. The original article has been corrected.
AB - In the online version of the article section 8 (Obesity), para 6, lines 1 to 5 which read as: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, of the GLP1-RA semaglutide 3 mg administered weekly and the combination of naltrexone and bupropione. should read: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, the GLP1-RA liraglutide 3 mg administered daily or semaglutide 2.4 mg administered weekly and the combination of naltrexone and bupropione. In online version of the article Section 8 (Obesity), table (New recommendation), third point which reads as: Medications for weight loss in obese subjects, including orlistat, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. should read: Medications for weight loss in obese subjects, including orlistat, liraglutide, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. The original article has been corrected.
UR - http://www.scopus.com/inward/record.url?scp=85128000240&partnerID=8YFLogxK
U2 - 10.1007/s40292-022-00508-7
DO - 10.1007/s40292-022-00508-7
M3 - Comment/debate
SN - 1120-9879
VL - 29
SP - 103
JO - High Blood Pressure and Cardiovascular Prevention
JF - High Blood Pressure and Cardiovascular Prevention
IS - 2
ER -
